Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

@article{Druker2000LessonsLF,
  title={Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.},
  author={Brian J. Druker and Nicholas Lydon},
  journal={The Journal of clinical investigation},
  year={2000},
  volume={105 1},
  pages={
          3-7
        }
}
  • B. Druker, N. Lydon
  • Published 2000
  • Biology, Chemistry
  • The Journal of clinical investigation
Protein kinases are a large family of homologous proteins comprising 2 major subfamilies, the protein serine/threonine kinases and protein tyrosine kinases (PTKs). Protein kinases function as components of signal transduction pathways, playing a central role in diverse biological processes such as control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein kinase inhibitors that can block or modulate diseases with abnormalities in these signaling… 

Figures and Tables from this paper

Tyrosine Kinase Receptor Inhibitors : A New Target for Anticancer Drug Development
TLDR
The role of TK receptors in development of cancer & the role of tyrosine kinase inhibitors on treating cancer are described.
Selective tyrosine kinase inhibitors
TLDR
This review concentrates on TK inhibitors which are either already in the clinic or likely to enter Phase I studies in the near future.
Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
TLDR
The current state-of-the-art using agents that target as prototypes Bcr-Abl, platelet-derived growth factor receptor (PDGFR), KIT, KIT (stem cell factor receptor), and epidermal growth factor receptors (EGFR) are reviewed.
From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
The confluence of two distinct but related activities in the past 10 years has dramatically accelerated efforts towards the discovery and development of novel drugs to treat cancer. The first is a
Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.
TLDR
Some of the more recent treatment strategies in non-small cell and small cell lung cancer targeted to dysregulated signaling pathways that are causally associated with tumor maintenance and progression are reviewed.
Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?
TLDR
Recent laboratory evidence suggests that the development of drug resistance is a possibility (via amplification of the bcr-abl fusion gene, overexpression of P-glycoprotein or binding of ST1571 to alpha1 acid glycoprotein) and that combination therapy including ST 1571 should be considered.
Protein Kinase Inhibitors: Insights into Drug Design from Structure
TLDR
This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available and which have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site, and into targeting noncatalytic domains.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
TLDR
An inhibitor (CGP 57148) of the Abl and platelet-derived growth factor (PDGF) receptor protein-tyrosine kinases from the 2-phenylaminopyrimidine class is described, which is highly active in vitro and in vivo and may have therapeutic potential for the treatment of diseases that involve abnormal cellular proliferation induced by Abl protein-tiesine kinase deregulation or PDGF receptor activation.
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
TLDR
CGP57148B, a 2-phenylaminopyrimidine derivative, has been shown to selectively inhibit the tyrosine kinase of ABL and BCR-ABL and it is concluded that this new agent may have significant therapeutic applications.
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
TLDR
It is shown that cells expressing an activated PDGFR tyrosine kinase, TEL-PDGFR, are sensitive to CGP 57148, and this compound may be useful for the treatment of a variety of BCR-ABL-positive leukemias and for treatment of the subset of chronic myelomonocytic leukemia patients with a Tel-PDgFR fusion protein.
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
The Philadelphia chromosome (Ph1), detected in virtually all cases of chronic myelogenous leukemia (CML), is formed by a reciprocal translocation between chromosome 9 and 22 that fuses Bcr-encoded
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
TLDR
A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein and it was found that this compound may be useful in the treatment of bcr–abl–positive leukemias.
Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
TLDR
A potent protein-tyrosine kinase inhibitor that shows selectivity for the PDGF receptor in vitro and in the cell, CGP 53716 may have therapeutic potential for the treatment of diseases involving abnormal cellular proliferation induced byPDGF receptor activation.
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
TLDR
Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bCr-abl and p185bcr-abl proteins.
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
TLDR
Evaluated antineoplastic activity of CGP57148B indicates that the continuous block of the oncogenic tyrosine kinase of Bcr/Abl protein is needed to produce important biologic effects in vivo.
...
1
2
3
4
...